Beta
Trial Radar KI
Die klinische Studie NCT06787560 für Knochenmarkversagensyndrom ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht
Zurück zur Suche

CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases Frühe Phase 1 20

Offene Rekrutierung
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06787560 untersucht Behandlung im Zusammenhang mit Knochenmarkversagensyndrom. Diese interventionsstudie der Frühe Phase 1 hat den Status offene rekrutierung und startete am 31. Januar 2025. Es ist geplant, 20 Teilnehmer aufzunehmen. Durchgeführt von Zhejiang-Universität wird der Abschluss für 31. Januar 2028 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 22. Januar 2025 aktualisiert.
Kurzbeschreibung
A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases
Ausführliche Beschreibung
This is a single-arm, open-label clinical trial to evaluate the safety and efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases. It is planned to enroll 12-20 participants in this trial.
Offizieller Titel

Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases

Erkrankungen
Knochenmarkversagensyndrom
Weitere Studien-IDs
  • TXB2024023
NCT-Nummer
NCT06787560
Studienbeginn (tatsächlich)
2025-01-31
Zuletzt aktualisiert
2025-01-22
Studienende (vorauss.)
2028-01-31
Geplante Rekrutierung
20
Studientyp
Interventionsstudie
PHASE
Frühe Phase 1
Status
Offene Rekrutierung
Stichwörter
CAR-T
Allo-HSCT
Immuno Deficiency Disorders
Primäres Ziel
Behandlung
Zuteilungsmethode
Nicht zutreffend
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
ExperimentellCD7 CAR-T cells（ CD7 chimeric antigen receptor T cells）
Patients or donors undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with CTX、Flu、VP-16 before CAR-T cells infusion. CAR-T cells could be transfused after 48 hours of preconditioning.
CD7 CAR-T cells injection
Each subject receive CD7 CAR T-cells by intravenous infusion
allo-HSZT
allogeneic hematopoietic stem cell transplantation
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Incidence of treatment-emergent adverse events (TEAEs)
Incidence of treatment-emergent adverse events
Up to 2 years after Treatment
Transplant related mortality rate
The proportion of patients who died after transplantation to the total number of transplant patients during the same period
Up to 100 days after Treatment
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Allogeneic hematopoietic stem cell transplant implantation rate
The proportion of the number of patients who achieved hematopoietic reconstitution to the total number of allogeneic hematopoietic stem cell transplantation patients in the same period.
Up to 100 days after Treatment
Time to neutrophil and platelet engraftment
The time for neutrophils and platelets to reach the implantation criteria after stem cell reinfusion
Up to 30 days after Treatment
Disease-feesurvival，DFS
The proportion of disease-free patients who survived to the total number of patients who transplanted allogeneic hematopoietic stem cells during the same period.
Up to 2 years after Treatment
Overall survival, OS
After transplantation until death from any cause.
Up to 2 years after Treatment
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Zugelassene Geschlechter
Alle

  • 1. Non-malignant blood and immune system diseases include: hereditary bone marrow failure, congenital immune deficiency, hemoglobinopathy and other non-malignant blood and immune system diseases,

    1. Confirmed hereditary bone marrow failure syndrome. Including: Fanconi anemia, congenital pure red cell aplastic anemia, congenital dyskeratosis, Scheux-Day syndrome, congenital neutropenia, various bone marrow failure related congenital thrombocytopenia and other unclassified congenital bone marrow exhaustion diseases;
    2. It meets the criteria of clinical manifestation, immune function and gene diagnosis of immune deficiency disease;
    3. Diagnosed with hemoglobinopathy and dependent on blood transfusions; serum ferritin levels are < 3000 μg/L, with cardiac and hepatic iron content indicating moderate or lower iron overload; documentation of iron chelation therapy (including prescriptions or invoices) for at least three months prior to screening is available; no hydroxyurea, ruxolitinib, decitabine, or cytarabine has been administered in the three months preceding enrollment. The spleen size must not extend beyond the umbilical horizontal line or the midline of the abdomen. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated, and suitable donors for related allo-HSCT are available.

  • 2. Serum total bilirubin ≤1.5 times the upper limit of normal value, serum Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal value range;

  • 3. Echocardiography showed Left ventricular ejection fraction (LVEF) >50%;

  • 4. Pulse oxygen saturation ≥92% (non-oxygen state);

  • 5. The estimated survival is more than 3 months;

  • 6. ECOG score 0-1;

  • 7. Abdominal B-ultrasonography and other examinations were performed to evaluate spleen size. Splenectomy should be evaluated before transplantation for patients with giant spleen;

  • 8. Women and men who are fertile must consent to the use of appropriate contraception before entering the study, during study participation, and for 6 months after transfusion (the safety of this therapy for the unborn child is not known, with unknown risks);

  • 9. Subjects who are willing to participate in the study are able to understand and have the ability to sign informed consent.

  • 1. People with a history of epilepsy or other central nervous system disorders;
  • 2. Epstein-Barr virus (EBV) DNA positive;
  • 3. People with a history of prolonged QT interval or serious heart disease;
  • 4. People with active hepatitis B or C virus;
  • 5. Tuberculosis, AIDS and other major infectious diseases;
  • 6. Sepsis, pulmonary infection, intestinal infection and other major organ infection and poor control, and/or hypersensitive C-reactive protein, procalcitonin significantly elevated;
  • 7. People who have previously received other clinical studies and gene therapy;
  • 8. Any situation that the investigator believes may increase the risk to the subject or interfere with the test results.
Zhejiang University logoZhejiang-Universität1067 aktive klinische Studien zum Erkunden
Yake Biotechnology Ltd. logoYake Biotechnology Ltd.
Verantwortliche Partei
He Huang, Hauptprüfer, Principal Investigator, First Affiliated Hospital of Zhejiang University
Zentrale Studienkontakte
Kontakt: He Huang, MD, 0571-87233772, [email protected]
Kontakt: Yongxian Hu, MD, 0571-87233772, [email protected]
1 Studienstandorte in 1 Ländern

Zhejiang

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, 310003, China
He Huang, MD, Kontakt, 0571-87233772, [email protected]
Yongxian Hu, MD, Kontakt, 0571-87233772, [email protected]
Offene Rekrutierung